BioMarin launches patient program for DMD

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) introduced the drisapersen ( PRO051), an antisense oligoribonucleotide that induces exon 51 skipping on the dystrophin gene, is under FDA and EMA review to t...